VCANBIO plans to acquire a 25% stake in Shanghai Zhongyuan Jisheng Company
VCANBIO announced plans to acquire a 25% stake in Shanghai Zhongyuan Jisheng Company for a transaction price of 3.8196 million yuan. This move aims to improve operational decision-making efficiency and increase resource investment in the adult health cell storage business. Upon completion of the transaction, Shanghai Zhongyuan Jisheng Company will become a wholly-owned subsidiary of VCANBIO, promoting the collaborative development of various business segments and building a complete business closed loop
According to the Zhitong Finance APP, VCANBIO (600645.SH) announced that in order to improve operational decision-making efficiency and continue to increase resource investment in adult health cell storage business, the company plans to use its own funds to acquire a 25% equity stake in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. (hereinafter referred to as "Shanghai Zhongyuan Jisheng") held by Shanghai Yanli Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Yanli"). The transfer price for this transaction is RMB 3.8196 million.
After the completion of this transaction, Shanghai Zhongyuan Jisheng will become a wholly-owned subsidiary of the company, which will not only improve operational decision-making efficiency but also fully utilize the cell life experience center and other hardware and software facilities, the initially scaled team, and market channels that have already been put into use by Shanghai Zhongyuan Jisheng. This will accelerate the integration of the company's various business segments and enhance collaborative efficiency, thereby building a complete business closed loop for the development of adult health cell storage business in the East China region
